Page 308 - Read Online

Page 8 of 9 Robinson et al. J Cancer Metastasis Treat 2019;5:39 I http://dx.doi.org/10.20517/2394-4722.2019.15

42. Shay JW, Wright WE. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett 2010;584:3819-25.
43. Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett
2018;592:2023-31.
44. Bojovic B, Booth RE, Jin Y, Zhou X, Crowe DL. Alternative lengthening of telomeres in cancer stem cells in vivo. Oncogene
2015;34:611-20.
45. de Lange T. How telomeres solve the end-protection problem. Science 2009;326:948-52.
46. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, et al. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503-14.
47. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-10.
48. O’Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010;11:171-81.
49. Schmidt JC, Cech TR. Human telomerase: biogenesis, trafficking, recruitment, and activation. Genes Dev 2015;29:1095-105.
50. Cho NW, Dilley RL, Lampson MA, Greenberg RA. Interchromosomal homology searches drive directional ALT telomere movement and
synapsis. Cell 2014;159:108-21.
51. Dilley RL, Verma P, Cho NW, Winters HD, Wondisford AR, et al. Break-induced telomere synthesis underlies alternative telomere
maintenance. Nature 2016;539:54-8.
52. Cesare AJ, Kaul Z, Cohen SB, Napier CE, Pickett HA, et al. Spontaneous occurrence of telomeric DNA damage response in the absence
of chromosome fusions. Nat Struct Mol Biol 2009;16:1244-51.
53. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science
2011;333:425.
54. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, et al. Loss of ATRX, genome instability, and an altered DNA damage response
are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012;8:e1002772.
55. Subhawong AP, Heaphy CM, Argani P, Konishi Y, Kouprina N, et al. The alternative lengthening of telomeres phenotype in breast
carcinoma is associated with HER-2 overexpression. Mod Pathol 2009;22:1423-31.
56. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, et al. Prevalence of the alternative lengthening of telomeres
telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011;179:1608-15.
57. Tanaka H, Abe S, Huda N, Tu L, Beam MJ, et al. Telomere fusions in early human breast carcinoma. Proc Natl Acad Sci U S A
2012;109:14098-103.
58. Gisselsson D, Jonson T, Petersen A, Strombeck B, Dal Cin P, et al. Telomere dysfunction triggers extensive DNA fragmentation and
evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci U S A 2001;98:12683-8.
59. Hampton OA, Den Hollander P, Miller CA, Delgado DA, Li J, et al. A sequence-level map of chromosomal breakpoints in the MCF-7
breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 2009;19:167-77.
60. Cleal K, Norris K, Baird D. Telomere length dynamics and the evolution of cancer genome architecture. Int J Mol Sci 2018;19:E482.
61. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. Massive genomic rearrangement acquired in a single catastrophic event
during cancer development. Cell 2011;144:27-40.
62. Maciejowski J, Li Y, Bosco N, Campbell PJ, de Lange T. Chromothripsis and kataegis induced by telomere crisis. Cell 2015;163:1641-54.
63. Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, et al. A gene expression signature classifying telomerase and ALT
immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 2009;28:3765-74.
64. Silvestre DC, Pineda JR, Hoffschir F, Studler JM, Mouthon MA, et al. Alternative lengthening of telomeres in human glioma stem cells.
Stem Cells 2011;29:440-51.
65. Robinson NJ, Schiemann WP. Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochim
Biophys Acta 2016;1866:320-9.
66. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, et al. Telomerase modulates Wnt signalling by association with target gene chromatin.
Nature 2009;460:66-72.
67. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, et al. Telomerase directly regulates NF- kappaB-dependent transcription. Nat Cell
Biol 2012;14:1270-81.
68. Ding D, Xi P, Zhou J, Wang M, Cong YS. Human telomerase reverse transcriptase regulates MMP expression independently of
telomerase activity via NF-kappaB-dependent transcription. FASEB J 2013;27:4375-83.
69. Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and
cancer cells. Science 2012;336:1549-54.
70. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, et al. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-
induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 2003;63:18-21.
71. Liu N, Ding D, Hao W, Yang F, Wu X, et al. hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1
transcription factor. Nucleic Acids Res 2016;44:8693-703.
72. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, et al. Direct activation of TERT transcription by c-MYC. Nat Genet
1999;21:220-4.
73. Yin S, Cheryan VT, Xu L, Rishi AK, Reddy KB. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers
cells. PLoS One 2017;12:e0183578.
74. Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, et al. MYC Inhibition Depletes Cancer Stem- like Cells in Triple-Negative Breast
Cancer. Cancer Res 2017;77:6641-50.
75. Henson JD, Reddel RR. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett
2010;584:3800-11.